IMAC (BACK) Competitors $0.04 0.00 (-9.75%) As of 04/30/2025 03:16 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock BACK vs. BTTX, UPHL, ACONW, AONC, DHACW, LFMDP, OTRKP, PIIIW, TALKW, and TOIIWShould you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Better Therapeutics (BTTX), UpHealth (UPHL), Aclarion (ACONW), American Oncology Network (AONC), Digital Health Acquisition (DHACW), LifeMD (LFMDP), Ontrak (OTRKP), P3 Health Partners (PIIIW), Talkspace (TALKW), and Oncology Institute (TOIIW). These companies are all part of the "healthcare" industry. IMAC vs. Better Therapeutics UpHealth Aclarion American Oncology Network Digital Health Acquisition LifeMD Ontrak P3 Health Partners Talkspace Oncology Institute IMAC (NASDAQ:BACK) and Better Therapeutics (NASDAQ:BTTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability. Do insiders & institutionals believe in BACK or BTTX? 5.8% of IMAC shares are held by institutional investors. Comparatively, 34.0% of Better Therapeutics shares are held by institutional investors. 12.3% of IMAC shares are held by company insiders. Comparatively, 51.4% of Better Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor BACK or BTTX? In the previous week, IMAC had 3 more articles in the media than Better Therapeutics. MarketBeat recorded 3 mentions for IMAC and 0 mentions for Better Therapeutics. IMAC's average media sentiment score of 0.00 equaled Better Therapeutics'average media sentiment score. Company Overall Sentiment IMAC Neutral Better Therapeutics Neutral Which has preferable valuation & earnings, BACK or BTTX? IMAC has higher revenue and earnings than Better Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIMAC$72.05K1.04-$9.42MN/AN/ABetter TherapeuticsN/AN/A-$39.76MN/AN/A Which has more volatility & risk, BACK or BTTX? IMAC has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, Better Therapeutics has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Is BACK or BTTX more profitable? Company Net Margins Return on Equity Return on Assets IMACN/A N/A -325.44% Better Therapeutics N/A N/A N/A Does the MarketBeat Community favor BACK or BTTX? Better Therapeutics received 5 more outperform votes than IMAC when rated by MarketBeat users. Likewise, 41.67% of users gave Better Therapeutics an outperform vote while only 0.00% of users gave IMAC an outperform vote. CompanyUnderperformOutperformIMACOutperform VotesNo VotesUnderperform Votes1100.00% Better TherapeuticsOutperform Votes541.67% Underperform Votes758.33% SummaryBetter Therapeutics beats IMAC on 5 of the 9 factors compared between the two stocks. Get IMAC News Delivered to You Automatically Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BACK vs. The Competition Export to ExcelMetricIMACSpecialty outpatient clinics IndustryMedical SectorNASDAQ ExchangeMarket Cap$83,000.00$1.23B$5.56B$7.83BDividend YieldN/A1.18%5.11%4.22%P/E RatioN/A7.3622.4818.48Price / Sales1.0414.25395.10103.59Price / CashN/A8.1038.1834.62Price / Book-0.050.786.774.25Net Income-$9.42M$36.27M$3.22B$248.23M7 Day PerformanceN/A2.60%1.50%0.89%1 Month PerformanceN/A-21.11%4.01%3.53%1 Year PerformanceN/A-64.86%16.16%5.08% IMAC Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BACKIMACN/A$0.04-9.8%N/A-99.0%$83,000.00$72,050.000.00180Upcoming EarningsNews CoverageBTTXBetter TherapeuticsN/A$0.00flatN/A-98.5%$20,000.00N/A0.0040UPHLUpHealthN/A$0.00flatN/A-100.0%$4,000.00$130M0.001,750High Trading VolumeACONWAclarionN/A$0.05+9.1%N/A-48.0%$0.00$45,724.000.007Positive NewsGap DownAONCAmerican Oncology NetworkN/A$5.11-14.8%N/A+64.9%$0.00$1.34B0.001,520Gap DownHigh Trading VolumeDHACWDigital Health AcquisitionN/A$0.04flatN/AN/A$0.00N/A0.00N/ALFMDPLifeMDN/A$24.69+1.6%N/A+8.8%$0.00$212.45M0.00230Upcoming EarningsShort Interest ↑Gap UpOTRKPOntrakN/A$0.24flatN/A-45.6%$0.00$10.84M0.00250PIIIWP3 Health PartnersN/A$0.01-15.7%N/A-80.3%$0.00$1.50B0.00500Positive NewsGap DownTALKWTalkspaceN/A$0.10+5.8%N/A-57.1%$0.00$187.59M0.00500Positive NewsTOIIWOncology InstituteN/A$0.04+25.4%N/A-69.0%$0.00$393.41M0.00660Short Interest ↓News CoveragePositive NewsGap UpHigh Trading Volume Related Companies and Tools Related Companies Better Therapeutics Competitors UpHealth Competitors Aclarion Competitors American Oncology Network Competitors Digital Health Acquisition Competitors LifeMD Competitors Ontrak Competitors P3 Health Partners Competitors Talkspace Competitors Oncology Institute Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BACK) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IMAC Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IMAC With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BACK Stock Free BACK Stock Alerts